352
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms

, , &
Pages 783-789 | Received 18 Apr 2024, Accepted 17 May 2024, Published online: 13 Jun 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.